Letter · 2015
In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite
Journal of Clinical Oncology, 33(13), 1511–1512 · Published 3 March 2015 · DOI 10.1200/jco.2014.59.8169
In brief
“In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite” is a 2015 letter by Thomas J. Herzog and 4 co-authors, published in Journal of Clinical Oncology. OpenAlex counts 1 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 1
- Most cited in
- 2015 (1)
- References
- 5
- Authors
- 5
Abstract
TO THE EDITOR: We would like to commend Oliver and McGuire 1 for their thoughtful editorial on antiangiogenic therapy and the role of clinical trial end points. We largely agree with the contentandtheirinsights,butwedotakeexceptiontothemischaracterizationthatwewouldrecommendoutrightapprovalofagents solelyonthebasisofprogression-freesurvivalwithoutconsidering the potential toxicities. Our article, 2 written on behalf of the Society of Gynecologic Oncology, explored the difficulties in proscribing overall… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Herzog, T. J., Coleman, R. L., Monk, B. J., Armstrong, D. K., & Alvarez, R. D. (2015). In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite. Journal of Clinical Oncology, 33(13), 1511–1512. https://doi.org/10.1200/jco.2014.59.8169
MLA 9
Herzog, Thomas J., et al. “In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite.” Journal of Clinical Oncology, vol. 33, no. 13, 2015, pp. 1511–1512. https://doi.org/10.1200/jco.2014.59.8169.
Chicago
Herzog, Thomas J., Robert Louis Coleman, Bradley J. Monk, Deborah Kay Armstrong, and Ronald David Alvarez. 2015. “In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite.” Journal of Clinical Oncology 33 (13): 1511–1512. https://doi.org/10.1200/jco.2014.59.8169.
Harvard
Herzog, T. J. et al. (2015) ‘In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite’, Journal of Clinical Oncology, 33(13), pp. 1511–1512. doi:10.1200/jco.2014.59.8169.
IEEE
T. J. Herzog, R. L. Coleman, B. J. Monk, D. K. Armstrong, and R. D. Alvarez, “In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite,” Journal of Clinical Oncology, vol. 33, no. 13, pp. 1511–1512, 2015, doi: 10.1200/jco.2014.59.8169.
BibTeX
@article{herzog2015assessing,
title = {{In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite}},
author = {Herzog, Thomas J. and Coleman, Robert Louis and Monk, Bradley J. and Armstrong, Deborah Kay and Alvarez, Ronald David},
journal = {Journal of Clinical Oncology},
year = {2015},
volume = {33},
number = {13},
pages = {1511--1512},
doi = {10.1200/jco.2014.59.8169},
url = {https://doi.org/10.1200/jco.2014.59.8169}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- surrogate endpoints
- ovarian cancer
- drug safety
- anti-angiogenic therapy
- regulatory approval
- overall survival
- progression-free survival
- toxicity prediction
Work with this paper
Most-cited papers in Mathematics
- Random ForestsLeo Breiman · Machine Learning · 2001 · 142,830 citations
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingYoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 113,923 citations
- Fitting Linear Mixed-Effects Models Using lme4Douglas M. Bates, Martin Maechler, Benjamin M. Bolker and 1 more · Journal of Statistical Software · 2015 · 100,328 citations
- The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Reuben M. Baron, David A. Kenny · Journal of Personality and Social Psychology · 1986 · 95,866 citations
- Using multivariate statisticsBarbara Gerson Tabachnick, Linda S. Fidell · 1983 · 79,867 citations
Questions about this paper
How do I cite this paper in APA style?
Herzog, T. J., Coleman, R. L., Monk, B. J., Armstrong, D. K., & Alvarez, R. D. (2015). In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite. Journal of Clinical Oncology, 33(13), 1511–1512. https://doi.org/10.1200/jco.2014.59.8169
How many times has this paper been cited?
1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Thomas J. Herzog, Robert Louis Coleman, Bradley J. Monk, Deborah Kay Armstrong, Ronald David Alvarez.
What is the DOI of this paper?
10.1200/jco.2014.59.8169, permanently at https://doi.org/10.1200/jco.2014.59.8169. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.